Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamy
about
sameAs
Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cellsAnaplastic lymphoma kinase: signalling in development and diseaseOncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesEmerging importance of ALK in neuroblastomaActivity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.The Novel Functions of High-Molecular-Mass Complexes Containing Insulin Receptor Substrates in Mediation and Modulation of Insulin-Like Activities: Emerging Concept of Diverse Functions by IRS-Associated ProteinsUnderstanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule InhibitorsHeat shock protein 90 inhibition: rationale and clinical potential.NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.Heat shock protein 90: translation from cancer to Alzheimer's disease treatment?A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapyInhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogeneSmall molecule inhibitors in acute myeloid leukemia: from the bench to the clinicMacrocyclic inhibitors of hsp90Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.Pathobiology of ALK+ anaplastic large-cell lymphoma.Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma.Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor.Targeting Hsp90: small-molecule inhibitors and their clinical development.High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma.Tyrosine kinase gene rearrangements in epithelial malignancies.ALK: a tyrosine kinase target for cancer therapy.Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.Treating ALK-positive lung cancer--early successes and future challenges.The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.The nucleophosmin-anaplastic lymphoma kinase oncogene interacts, activates, and uses the kinase PIKfyve to increase invasiveness.Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive LymphomasSynuclein gamma protects HER2 and renders resistance to Hsp90 disruption.Analysis of conformational determinants underlying HSP90-kinase interactionProteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometryThe use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphomaPediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies.Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers.CCDC6: the identity of a protein known to be partner in fusion.
P2860
Q24293321-B9012457-DBC5-4652-8F85-049E46D8049EQ24312329-E46D0BE1-E45A-47CB-9480-38CEB5A3546FQ26768158-D93B71C5-FD7D-4C97-AF22-AB66246D921FQ26858819-70EFB344-0706-4D8F-BFFB-B65519337AB6Q27851585-72BEDAE6-DA47-4501-ACC2-8F37B092CB3AQ28088661-68403D83-E2F7-4455-A9F1-685CC0176CC5Q28546245-5DDF90A1-1DF4-4E91-8759-601F5C11D146Q30418761-E3AC1355-8358-461D-BFFF-48FD0A2DA8A8Q30831857-EC86E9B6-81F1-4265-8A57-50F8AA245348Q30855123-4DE9AD64-4D6F-49C7-BEB6-941BC191564FQ33588432-4EA71CDE-C659-4B2D-A8E1-86F268E32F62Q33924261-7BAB4277-A022-4CC7-AFF9-104116A528CCQ34297784-09CDAE6F-83BE-44EC-9D56-811CB1AD5F4AQ34360164-AFB205CA-479D-448C-AC80-82C739A8E91AQ34593929-5CAD30A9-3111-4376-A55F-1806D52047B1Q34817365-2071D8C7-F9DF-4D2F-A28B-C0CEC7539455Q35017513-ED8D8790-7518-40C7-ACBE-9F1F783085B6Q35575978-1CA58174-A697-4C39-975D-A1BFB7CA0217Q36007756-8E7F27C3-AD13-43DD-AB1F-0EBC0B4519F2Q36145016-C4DDDDD2-1676-4BB0-B133-EBBBD024556FQ36193920-BDDB289A-FAC3-4F55-92A2-340CDB022F41Q36879252-5A695AAB-DBAB-405B-8459-F4F503D42568Q37222845-8A2CB546-3678-4DA3-98CE-AD2BA62D2326Q37385234-7517BEEF-4E97-46A3-9907-F049E1097E97Q37515966-7D433128-E943-46E5-9C1B-2A2EC5DB8BD0Q37518624-0B9D83D6-6BC8-4B8B-AD2A-EFAEC906310DQ37919976-38D332A9-6309-490B-85EA-D4803CA7B06DQ37999657-9D62D134-4738-4F21-955B-C358D967DC50Q38101044-7F2EAB3C-F04C-4935-9F69-58C99380E492Q38241120-4D04446B-F0B8-4A58-A9A6-0694F5D74895Q38422343-26795CCC-CCAA-406D-BACA-3335BB9A3F05Q38644718-C08CEC13-E6F2-4EFB-A855-FFA1E4C1E428Q38977711-BAD220A8-09F3-4B91-AF86-8AA6A3B85166Q39127414-2E8FF35F-68F9-4D7B-8C76-9E73AF0C4761Q39897523-A39C8951-107E-47FD-A5D3-A7E3C7001597Q41116766-08301375-5B55-4BEE-998E-90D613C7D5E5Q41838768-8818B093-D701-42E1-9E41-B200F016AA97Q41942675-E584819B-C4C1-4F75-B941-CD35F64768C6Q47134648-4E3A1A12-3956-4565-8F9E-0DA0EF7C8806Q47634740-061B8977-ECBF-4C9D-90DE-9A3EA7912177
P2860
Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamy
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Nucleophosmin-anaplastic lymph ...... lylamino,17-demethoxygeldanamy
@nl
type
label
Nucleophosmin-anaplastic lymph ...... lylamino,17-demethoxygeldanamy
@nl
prefLabel
Nucleophosmin-anaplastic lymph ...... lylamino,17-demethoxygeldanamy
@nl
P2093
P3181
P1433
P1476
Nucleophosmin-anaplastic lymph ...... amino,17-demethoxygeldanamycin
@en
P2093
Angelo Rosolen
Brunangelo Falini
Paolo Bonvini
Tamara Gastaldi
P304
P3181
P356
10.1182/BLOOD-2016-05-717793
P407
P577
2002-03-01T00:00:00Z